The R21/Matrix-M Malaria vaccine is the first example where a vaccine has been directly licensed by a university directly to a large-scale manufacturer, rather than a spinout, a biotech or pharma company.
The Nuffield Department of Medicine’s R21/Matrix-M Malaria Vaccine Clinical Development Programme’s success provides a notable example of innovation and strategic commercial partnering for large scale manufacture and impact with the University leading the clinical development, providing a new high efficacy low-cost product for saving the lives of millions of African children and supporting eventual malaria eradication.